Discovery and development of anti-HBV agents and their resistance

Kyun Hwan Kim, Nam Doo Kim, Baik Lin Seong

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Hepatitis B virus (HBV) infection is a prime cause of liver diseases such as hepatitis, cirrhosis and hepatocellular carcinoma. The current drugs clinically available are nucleot(s)ide analogues that inhibit viral reverse transcriptase activity. Most drugs of this class are reported to have viral resistance with breakthrough. Recent advances in methods for in silico virtual screening of chemical libraries, together with a better understanding of the resistance mechanisms of existing drugs have expedited the discovery and development of novel anti-viral drugs. This review summarizes the current status of knowledge about and viral resistance of HBV drugs, approaches for the development of novel drugs as well as new viral and host targets for future drugs.

Original languageEnglish
Pages (from-to)5878-5908
Number of pages31
JournalMolecules
Volume15
Issue number9
DOIs
Publication statusPublished - 2010 Sep 1

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Chemistry (miscellaneous)
  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Organic Chemistry

Cite this